I'm LongbridgeAI, I can summarize articles.10X Genomics (TXG) closed the week at $80.65, down 13.74%. The S&P 500 gained 1.15%, leaving the stock roughly 14.89 percentage points behind the benchmark. The daily bars show an up-and-down path: Monday (Oct 5) firmed to $97.74, Tuesday (Oct 6) spiked to a high of $102.81 before sliding to $80.66, Wednesday (Oct 7) fell further to $76.10, Thursday (Oct 8) bottomed around $70.94 and settled at $77.28, and Friday (Oct 9) recovered to $80.65. The stock swung 34.
The Week
10X Genomics (TXG) closed the week at $80.65, down 13.74%. The S&P 500 gained 1.15%, leaving the stock roughly 14.89 percentage points behind the benchmark. The daily bars show an up-and-down path: Monday (Oct 5) firmed to $97.74, Tuesday (Oct 6) spiked to a high of $102.81 before sliding to $80.66, Wednesday (Oct 7) fell further to $76.10, Thursday (Oct 8) bottomed around $70.94 and settled at $77.28, and Friday (Oct 9) recovered to $80.65. The stock swung 34.09% from low to high, a bumpy week marked by a sharp pull-back after an early rally.
Key Events
The week mixed new research deals with insider-selling pressure. On Oct 7, 10x Genomics announced a collaboration to advance single-cell and spatial applications across solid tumours and blood cancers; a day later it detailed a partnership with Fred Hutchinson Cancer Center for cancer technologies. At the same time, the CEO’s share reduction and SimplyWall’s overvaluation warning coincided with the sharpest moves: the stock first rose more than 9%, then fell more than 13% within the same session on Tuesday. Sector-wise, several life-science names hit 52-week highs, but TXG’s own sell-off kept it out of that momentum.
Analyst Ratings
Nineteen analysts cover TXG: 6 rate it buy, 1 overweight, 12 hold, and none recommend underweight or sell. The consensus rating is buy, while the consensus target of $69.47 sits about 13.87% below the current price of $80.65. The target range is wide, from a high of $110.00 to a low of $40.00, pointing to split views on valuation. Within the life-science tools and services industry, TXG ranks 9th out of 54 companies.
The Week Ahead
Macro data leads the calendar. On Oct 14, the US reports CPI and core CPI: core CPI is expected at 2.5% year-on-year from 2.4%, and headline CPI at 3.7% from 3.4%, with month-on-month figures due the same day. The prints could weigh on rate-sensitive tech and biotech valuations. Earlier in the week, Oct 13 brings NFIB small-business optimism and existing-home sales data. On the company side, the next test is whether the new partnerships translate into firmer guidance or commercial traction, and whether valuation concerns ease.
In Short
The pull-back landed mostly between Tuesday and Thursday, alongside the CEO’s share sale and a high-valuation warning, while new cancer-research collaborations failed to lift the tape. Analyst positioning is cautious rather than aggressive: 12 holds against 6 buys and 1 overweight, and the consensus target sits below spot. Valuation shows a PB near 12.73x with negative earnings, so profit momentum is still missing. The latest session also showed large-lot money leaning defensively. What comes next hinges on whether core CPI stays sticky, and whether the collaboration news gets followed by concrete product or revenue signals.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.